NV1205 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
20副腎白質ジストロフィー3

20. 副腎白質ジストロフィー


臨床試験数 : 53 薬物数 : 88 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 123
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03196765
(ClinicalTrials.gov)
August 20185/5/2017Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With AdrenoleukodystrophyPhase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)X-Linked AdrenoleukodystrophyDrug: Sobetirome (NV1205)NeuroVia, Inc.NULLWithdrawn4 Years18 YearsMale0Phase 1/Phase 2Argentina;Australia;Chile;Colombia;France;Russian Federation;Ukraine;United Kingdom
2EUCTR2017-001684-21-GB
(EUCTR)
20/04/201826/10/2017Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) Childhood Cerebral Adrenoleukodystrophy (CCALD);Therapeutic area: Diseases [C] - Hormonal diseases [C19]Product Name: Sobetirome
Product Code: NV1205
INN or Proposed INN: Sobetirome
Other descriptive name: QTXEW2-04-AF, EW2, GC-1, QRX-431
Neurov Acquisition LLCNULLNot Recruiting Female: no
Male: yes
25 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Argentina;Ukraine;Australia;Russian Federation;Chile;Colombia;United Kingdom
3EUCTR2017-001684-21-FR
(EUCTR)
23/03/2018Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) Childhood Cerebral Adrenoleukodystrophy (CCALD);Therapeutic area: Diseases [C] - Hormonal diseases [C19]Product Name: Sobetirome
Product Code: NV1205
INN or Proposed INN: Sobetirome
Other descriptive name: QTXEW2-04-AF, EW2, GC-1, QRX-431
NeuroVia, Inc.NULLNA Female: no
Male: yes
25 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Argentina;Ukraine;Australia;Russian Federation;Chile;Colombia;United Kingdom